| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Sri Lanka Pharmaceuticals and Healthcare Report Q3 2010
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
Sri Lanka |
Published |
21 July 2010 |
Number of Pages |
43 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
According to the drug expenditure forecast model, sales of pharmaceuticals in Sri Lanka are expected to increase from LKR38.97bn (U$339mn) in 2009 to LKR43.88bn (US$388mn) in 2010. Due to the strengthening rupee, this equates to 12.6% growth in local currency terms and 14.2% in US dollar terms. Although these projections are below the market's 2004-2009 compound annual growth rate (CAGR) of 15.5%, they compare favourably with the regional average of 11.6%.
Sri Lanka has an enlightened pharmaceutical sector. During the 1970s, the country demonstrated that a state buying agency linked to a national formulary was a viable and powerful instrument for reducing drug costs without compromising quality. It also had the important attributes of preserving valuable foreign reserves, rationalising medicine usage and for supplying essential drugs at reasonable prices to the whole community.
Sri Lanka receives a score of 40.7 out of 100 on the Pharmaceuticals & Healthcare BERs for Q310. This makes it the region’s 14th most attractive market, behind Vietnam (42.1) and ahead of Bangladesh (39.7). Sri Lanka scores above the regional average for country risk, but is let down by industry rewards, country rewards and industry risks.
Counterfeit medicines are a moderate problem in Sri Lanka. In mid-2009, doctors claimed that nearly a third of pharmaceuticals they dispense are fake and thereby endanger the health of patients. However, the Ministry of Health says the issue is overblown and the prevalence of imitation drugs is low. The stance is somewhere in between. As with all other countries, the true prevalence of counterfeits in Sri Lanka is unknown and generally exaggerated or underplayed depending on which stakeholder is asked. The Burden of Disease Database (BoDD) reveals that the number of disability-adjusted life years (DALYs) lost to non-communicable diseases in Sri Lanka will increase from 2,237,788 in 2009 to 2,891,156 in 2010 – a rise of 29%. Meanwhile, the number of DALYs lost to communicable diseases will fall by 51%, from 346,265 to 168,196.
Domestic manufacturers account for just 10% of the country's US$339mn pharmaceutical market and Sri Lanka's reliance on imported drugs is a concern. Fluctuations in the prices of active pharmaceutical ingredients (APIs) – as seen in 2008, when the price of crude oil reached record highs and then dropped – cause the cost of finished medicines to change wildly. By stimulating local production, a steadier supply of medicines will be achieved, which is of great importance to the state, prescribers and patients.
Last Viewed
Sri Lanka Pharmaceuticals and Healthcare Report Q3 2010TUI AG (TUI1) - Financial and Strategic Analysis Review
Glucose Monitoring Devices Market Worldwide (2010 – 2014)
Qwest Communications International Inc. - SWOT Analysis
GN Store Nord AS (GN) - Financial and Strategic Analysis Review
Healthcare and Medical Company Profiles
Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Genium Bionic Prosthetic System Represents the First Intuitive Knee
AdCare continues nursing facilities acquisitions strategy
AdCare Purchases US$27.3Mn Nursing Facilities in Arkansas to Drive Strong Revenue Growth
Micromet to Develop Blinatumomab with the National Cancer Institute
AstraZeneca to Develop Targacept’s Product Candidate AZD1446 as a Treatment for Alzheimer’s
Market Insights
Currently there are no Market Insights in this sector.
